Cancer Control Journal Vol 3, No 6
CME Pretest

In this isssue, the topic of genitourinary cancer is addressed. First, answer the pretest questions below. After reading the articles, proceed with answering the CME posttest questions.

This Journal provides 4 hours of Category I Continuing Medical Education

Complimentary CME Credits

Physicians can earn up to 4 credit hours of Category I for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions on the posttest at the end of this issue. Complete instructions are given on the posttest pages. Every successfully answered 10 questions will earn 1 credit hour. CME is presented by an unrestricted educational grant from Bristol-Myers Oncology Division.

Educational Objectives

After reading this issue, clinicians will be expected to:

• describe the latest approaches to a variety of urologic neoplasms;
• recognize the potential of cytokine use in adjuvant therapy of breast cancer; and
• manage infections occuring in HIV patients with cancer.

This program was planned in accordance with ACCME Essentials.
Release Date: December 1, 1996, Expiration Date: December 1, 1997

Pretest

1. Approximately what proportion of patients with metastatic prostate cancer will experience "flutamide withdrawal" benefit after combined androgen blockade?

a. 15%

b. 30%

c. 60%

d. 90%

2. What is the incidence of ejaculatory impotence after retroperitoneal nerve dissection for low-stage testis cancer using defined templates and nerve-sparing techniques?

a. less than 5%

b. 10% to 15%

c. 20% to 30%

d. over 50%

3. What genetic abnormality is most commonly seen in urothelial dysplasias and CIS?

a. bcl-2

b. loss of heterozygosity on chromosome 9

c. p53 mutation

d. adult T-cell leukemia